£195 / $340 / €245
Based in New Jersey in the US, Cordis develops and manufactures medical devices for the treatment of vascular disease, and through its Biosense Webster subsidiary, provides cardiac diagnostic, therapeutic and mapping tools. At the time of its formation in 1957, the company was called Medical Development Corporation; its name was changed in 1959 to Cordis (“of the heart”) to reflect its primary therapeutic focus.
Cordis now focuses on access, diagnostic and therapeutic products for cardiology procedures, products to diagnose, access and treat lower extremity disease, and the Incraft stent-graft system, the company’s new investigational device for treating abdominal aortic aneurysm (AAA). The company is also offers globally ExoSeal, its first vascular closure device.
The Cordis Medical Device Company Report provides a full review of the company's medical device activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures and litigation. Sections are also included on products, corporate strategy and R&D.
Whatever your interest or involvement, evaluating the performance, success, failures and developments of medical companies is critical. Espicom’s Medical Device Company Reports have been regularly published for over 20 years, and these critically acclaimed and respected management reports provide a complete review of leading players in the field.
Research and Development
Manufacturing and Distribution
Mergers and Acquisitions
Key Corporate Events
The report was produced as part of Medical Device Companies Analysis (MDCA). For more information on MDCA, click here.